MMC Health Care Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: MMC Health Care Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $1.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

MMC Health Care Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $1.6M Trade | TransData Nexus

MMC Health Care Limited

Indian Pharmaceutical Exporter · Antihistamines & Allergy Specialist · $1.6M Total Trade · DGFT Verified

MMC Health Care Limited is an Indian pharmaceutical exporter with a total trade value of $1.6M across 3 products in 2 therapeutic categories. Based on 60 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Chlorpheniramine ($950.0K), Glucosamine ($473.2K), Chondroitin ($131.0K).

MMC Health Care Limited — Export Portfolio & Destination Treemap

MMC Health Care Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is MMC Health Care Limited? — Company Overview & Market Position

MMC Health Care Limited is an Indian pharmaceutical exporter established on February 28, 1996, in Chennai, Tamil Nadu. The company is registered under the Corporate Identification Number (CIN) U93090TN1996PLC034651. It operates as a public limited company, classified as a non-government entity. The authorized capital stands at ₹25 million, with a paid-up capital of ₹13.67 million. As of March 31, 2024, the company reported a total export value of $1.6 million USD, encompassing 60 shipments across three products in two therapeutic categories. The registered office is located at No.34-B, SIDCO Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, 600124, India.

What Does MMC Health Care Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Chlorpheniramine$950.0K 2Glucosamine$473.2K

Product Portfolio — Top 3 by Export Value

MMC Health Care Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Chlorpheniramine	Antihistamines & Allergy	$950.0K	19	2.1%	2
2	Glucosamine	Nutritional Supplements	$473.2K	32	3.6%	8
3	Chondroitin	Nutritional Supplements	$131.0K	9	2.6%	9

MMC Health Care Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $1.6M. The top category is Antihistamines & Allergy (61.1% of portfolio), followed by Nutritional Supplements (38.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

MMC Health Care Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

MMC Health Care Limited operates its manufacturing facility in Thirumazhisai, Chennai, Tamil Nadu. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and specialized manufacturing capabilities are not publicly disclosed.

3Key Leadership

The leadership team at MMC Health Care Limited includes:

Nageswararao Gupta Manepalli: Managing Director, appointed on September 20, 2018.

Sureshbabu Makam: Director, serving since September 28, 2015.

Raghva Tayaru Aswani Manepalli: Director, appointed on March 1, 2019.

Padmaja Rani Manepalli: Director, serving since September 20, 2018.

Someswara Rao Manepalli: Director, appointed on September 29, 2018.

These individuals collectively oversee the strategic direction and operations of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does MMC Health Care Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

MMC Health Care Limited's export activities are primarily focused on the production and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's export portfolio is concentrated in two therapeutic categories: Antihistamines & Allergy (61.1%) and Nutritional Supplements (38.9%). The top three exported products are:

Chlorpheniramine: $950,000 USD, ranking #2 with a 2.1% market share.

Glucosamine: $473,000 USD, ranking #8 with a 3.6% market share.

Chondroitin: $131,000 USD, ranking #9 with a 2.6% market share.

These figures indicate a diversified product range within the company's export portfolio. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available.

2Emerging Markets

MMC Health Care Limited's export data does not provide specific information regarding its presence in emerging markets such as Africa, Latin America, and Southeast Asia. The company's export portfolio is concentrated in two therapeutic categories: Antihistamines & Allergy (61.1%) and Nutritional Supplements (38.9%). The top three exported products are:

MMC Health Care Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding MMC Health Care Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data indicates a diversified product range within the company's export portfolio. However, specific details regarding the company's FDA status are not publicly available.

2WHO & EU GMP

Specific details regarding MMC Health Care Limited's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The company's export data indicates a diversified product range within the company's export portfolio. However, specific details regarding the company's compliance with international quality standards are not publicly available.

3CDSCO & Indian Regulatory

Specific details regarding MMC Health Care Limited's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available. The company's export data indicates a diversified product range within the company's export portfolio. However, specific details regarding the company's compliance with Indian regulatory requirements are not publicly available.

MMC Health Care Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Specific details regarding MMC Health Care Limited's top competitors in overlapping categories, market share comparison, and head-to-head analysis are not publicly available. The company's export data indicates a diversified product range within the company's export portfolio. However, specific details regarding the competitive landscape are not publicly available.

2Key Differentiators

Specific details regarding MMC Health Care Limited's unique strengths, competitive advantages, and product portfolio distinctions are not publicly available. The company's export data indicates a diversified product range within the company's export portfolio. However, specific details regarding the company's key differentiators are not publicly available.

3Strategic Position

Specific details regarding MMC Health Care Limited's current strategic direction, including focus on generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, and future outlook are not publicly available. The company's export data indicates a diversified product range within the company's export portfolio. However, specific details regarding the company's strategic position are not publicly available.

Buyer Due Diligence Brief — Evaluating MMC Health Care Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Specific details regarding MMC Health Care Limited's overall track record, export volume and consistency, and reliability indicators are not publicly available. The company's export data indicates a diversified product range within the company's export portfolio. However, specific details regarding the company's supplier assessment are not publicly available.

2Certifications to Verify

Importers should verify the following certifications when considering MMC Health Care Limited as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Ensure adherence to European Union Good Manufacturing Practice standards.

Frequently Asked Questions — MMC Health Care Limited

How many pharmaceutical products does MMC Health Care Limited export from India?

MMC Health Care Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Chlorpheniramine ($950.0K), Glucosamine ($473.2K), Chondroitin ($131.0K). Total export value is $1.6M.

What is MMC Health Care Limited's total pharmaceutical export value?

MMC Health Care Limited's total pharmaceutical export value is $1.6M, based on 60 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does MMC Health Care Limited cover?

MMC Health Care Limited exports across 2 therapeutic categories. The largest are Antihistamines & Allergy (61.1%, 1 products), Nutritional Supplements (38.9%, 2 products).

Get Full MMC Health Care Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.